China Approves Sovleplenib in Two Autoimmune Blood Diseases

Company HUTCHMED Event Type NMPA approvals (previously missed 19 Nov event) Modality Oral small molecule Asset Sovleplenib Target Spleen tyrosine kinase (Syk) Disease Area Chronic primary immune thrombocytopenia; warm autoimmune hemolytic anemia Summary China approved oral Syk inhibitor sovleplenib for previously treated chronic primary immune…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *